Delisting risk
PharmaCyte Biotech (PMCB)
Develops CypCaps, a cell-encapsulation pancreatic cancer therapy candidate.
$0.4808
At close−0.01 (−1.50%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions33 holders · as of Mar 31, 2026 | 9.01% | 967.3K shares | |
| Insiders5 holders · as of Jan 7, 2026 | 6.45% | 692.9K shares | |
| Otherremainder | 84.54% | 9.08M shares |
10.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
33 holders · 967.3K shares · 11 new positions · 17 increased · 7 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Citadel Advisors LLC | 359.5K | 3.35% | +129.8K | May 15, 2026 |
| Geode Capital Management, LLC | 195.7K | 1.82% | +71.8K | May 15, 2026 |
| Renaissance Technologies LLC | 56.5K | 0.53% | −37.5K | May 14, 2026 |
| XTX Topco Ltd | 52.4K | 0.49% | +27.9K | May 15, 2026 |
| Vanguard Capital Management LLC | 51.5K | 0.48% | +51.5Knew | May 15, 2026 |
| Virtu Financial LLC | 37.5K | 0.35% | +37.5Knew | May 14, 2026 |
| Northern Trust Corp | 35.6K | 0.33% | 0 | May 14, 2026 |
| Schonfeld Strategic Advisors LLC | 27.0K | 0.25% | +831 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Mitchell P. Kopin | 9.99% | 695.7K | 13G | Nov 7, 2025 ↗ |
| Ayrton Capital LLC | 9.90% | 774.1K | 13G | Feb 13, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 5, 2026 | Jonathan Schechterdirector | Purchase | 20,000 | $0.7776 | 152,500 |
| Jan 6, 2026 | Jonathan Schechterdirector | Purchase | 20,000 | $0.7904 | 172,500 |
| Jan 7, 2026 | Jonathan Schechterdirector | Purchase | 20,000 | $0.8436 | 192,500 |
| Jan 5, 2026 | Joshua Silvermandirector, officer: CEO and President | Purchase | 30,000 | $0.7831 | 346,250 |
| Jan 6, 2026 | Joshua Silvermandirector, officer: CEO and President | Purchase | 30,000 | $0.7889 | 376,250 |
| Jan 7, 2026 | Joshua Silvermandirector, officer: CEO and President | Purchase | 40,000 | $0.8329 | 416,250 |
CongressHouse and Senate disclosures
Not reported.
